全文获取类型
收费全文 | 110篇 |
免费 | 3篇 |
专业分类
儿科学 | 4篇 |
基础医学 | 10篇 |
临床医学 | 13篇 |
内科学 | 29篇 |
皮肤病学 | 10篇 |
神经病学 | 9篇 |
特种医学 | 1篇 |
外科学 | 20篇 |
预防医学 | 1篇 |
眼科学 | 1篇 |
药学 | 7篇 |
肿瘤学 | 8篇 |
出版年
2022年 | 2篇 |
2021年 | 1篇 |
2015年 | 3篇 |
2014年 | 1篇 |
2013年 | 5篇 |
2012年 | 3篇 |
2011年 | 1篇 |
2010年 | 1篇 |
2009年 | 3篇 |
2007年 | 1篇 |
2006年 | 4篇 |
2004年 | 3篇 |
2003年 | 2篇 |
2002年 | 2篇 |
2001年 | 3篇 |
2000年 | 1篇 |
1999年 | 4篇 |
1998年 | 6篇 |
1997年 | 10篇 |
1996年 | 10篇 |
1995年 | 5篇 |
1994年 | 4篇 |
1993年 | 4篇 |
1992年 | 5篇 |
1991年 | 4篇 |
1990年 | 3篇 |
1989年 | 1篇 |
1988年 | 2篇 |
1987年 | 2篇 |
1986年 | 2篇 |
1985年 | 3篇 |
1984年 | 2篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1978年 | 1篇 |
1976年 | 1篇 |
1970年 | 2篇 |
1958年 | 2篇 |
1957年 | 1篇 |
排序方式: 共有113条查询结果,搜索用时 15 毫秒
1.
SHIGEKI OCHI MORIKAZU ONJI KAZUHITO SHIRAISHI KYOKO OHTU TOMOHIRO AKAO YOSHITO YANO NOBUYUKI TAKEI HIKARU MATSUI YASUYUKI OHTA MASAKICHI UMEDA 《Journal of gastroenterology and hepatology》1991,6(6):599-602
To clarify the prevalence of concurrent infection with hepatitis C virus (HCV), hepatitis B virus (HBV) and human T cell leukaemia virus (HTLV), we measured HCV antibody in the population of a district endemic for HBV and HTLV infection. Blood samples were collected in June 1990 from 579 inhabitants of four islands of Uwa Bay in the southwest of Ehime Prefecture in Japan. Anti-HCV antibody against C100-3 protein was detected using an enzyme-linked immunosorbent assay kit (Ortho Diagnostics). Thirteen of the 579 inhabitants (2.2%) were positive for anti-HCV, and this prevalence rate was not significantly different from the frequency of anti-HCV in Tokyo blood donors. A total of 11% (64 of 579) of the subjects were positive for HBsAg and 3.3% (19 of 579) were positive for anti-HTLV. These frequencies of HBsAg and anti-HTLV positivity were distinctly higher than the respective means of Japanese. All anti-HCV positive individuals were negative for HBsAg and anti-HTLV, while 54% (7 of 13) had increased alanine aminotransferase levels. These data suggest that the prevalence of HCV infection is not high even in an area endemic for HBV and HTLV infection. 相似文献
2.
The Preclinical Safety Evaluation of Human Monoclonal Antibody against Cytomegalovirus 总被引:1,自引:0,他引:1
MATSUZAWA KEIKO; KOYAMA TAMOTSU; SUGAWARA SHIGEKI; IKEGAWA SUNAO; ASANO SATOSHI; SASAKI SATOSHI; TOMIYAMA TAKAMI; KASAHARA YOSHINORI; OKAMIYA YOSHIAKI; INOUE KYOKO; OHTA TOMOHIRO; MAKITA TOKUTARO 《Toxicological sciences》1992,19(1):26-32
The human monoclonal antibody against cytomegalovinis (Mab C23)was examined pharmacokinetically and toxicologically as partof the preclinical studies prior to approval for human use.Rats given repeated intravenous administrations of Mab C23 producedno antibodies against Mab C23 and maintained a blood Mab C23level in a dose-dependent manner. However, pregnant rabbitsproduced antibodies against Mab C23. The half-life of Mab C23in plasma was 15.9 days in rats, which was similar to that ofnormal human serum -globulin (NHSG). Neither behavioral effectsnor circulatory disturbance was found in mice, rats, and dogseven after a single intravenous injection of 100 or 200 mg/kg,which corresponds to 50 or 100 times the intended clinical dosage.The repeated doses of 2, 10, or 20 mg/kg of Mab C23 on six occasionswith 1- or 2-week intervals elicited a transient decrease inleukocyte counts in rats given 10 or 20 mg/kg, but no adverseeffects in cynomolgus monkeys. Mab C23 did not cause any reproductiveor developmental toxicity when administered to rats and rabbitsat dose levels of 20 mg/kg or less. However, pregnant animalsshowed lower plasma levels of Mab C23 than non-pregnant animals.The chromosomal aberration test disclosed no clastogenicityin human lymphocytes. An immunostaining for Mab C23 revealedno localizations in several tissues of cynomolgus monkeys givenintravenous doses of Mab C23. The preclinical safety evaluationin animals other than rabbits, which produced no antibodiesagainst Mab C23, showed that the behavior of Mab C23 is pharmacokineticallysimilar to that of NHSG and is as safe as NHSG, which has longbeen used as a biological agent. However, because there wasa difference in blood levels of Mab C23 between pregnant andnonpregnant animals, its clinical administration to pregnantpatients should differ from that to non-pregnant patients. 相似文献
3.
4.
Signet-ring cell carcinoma of the prostate effectively treated with maximal androgen blockade 总被引:3,自引:0,他引:3
KEIGO AKAGASHI HITOSHI TANDA SHUJI KATO SHIGEKI OHNISHI HISAO NAKAJIMA AKIHITO NANBU TOSHIKAZU NITTA MIKIO KOROKU 《International journal of urology》2003,10(8):456-458
Primary signet-ring cell carcinoma (SRCC) of the prostate is very rare and has a poor prognosis, even when treated with aggressive therapy. We report herein a case of a 72-year-old man with prostatic SRCC. The patient had a tumor that extended directly to the rectum. Maximal androgen blockade was started and 20 months later, the patient was alive without evidence of recurrence. The present case of prostatic SRCC responded well to medical therapy, however, tumors can recur after a long period of time. Therefore, adjuvant therapy is recommended. 相似文献
5.
SHIGEKI MORI YUTAKA AOYAGI MASAHIKO YANAGI YASUFUMI SUZUKI HITOSHI ASAKURA 《Journal of gastroenterology and hepatology》1998,13(6):610-619
N-Acetylglucosaminyltransferase III (GnT III) catalyses the addition of N-acetylglucosamine through a β 1–4 linkage to the mannose of the trimannosyl core, resulting in conversion of the concanavalin A (Con A)-reactive glycan into a non-reactive state. In this study, we measured GnT III activity to evaluate its diagnostic efficacy and its therapeutic effect on hepatocellular carcinoma (HCC). Concanavalin A-non-reactive fraction of serum transferrin (Tf) was also determined since the sugar chains of Tf are one of the possible candidates for the product of GnT III. Serum samples (159) were used from patients with HCC (89), liver cirrhosis (30), chronic hepatitis (19), alpha-fetoprotein (AFP) producing gastric carcinoma metastatic to the liver (five) and healthy controls (16). N-Acetyl-glucosaminyltransferase III activity was determined by high performance liquid chromatography. The reactivity of serum Tf to Con A was also analysed in 21 paired HCC samples before and after treatment by crossed immuno-affinoelectrophoresis. N-Acetylglucosaminyltransferase III activity from the HCC group (153 ± 72 pmol/mL/h) was significantly higher than that from liver cirrhosis (99 ± 67 pmol/mL per h), chronic hepatitis (84 ± 39pmol/mL per h) and the normal controls (62 ± 16pmol/mL per h). N-Acetylgiucosaminyltransferase III activity of 21 patients with HCC was significantly reduced after treatment such as transcatheter arterial chemoembolization and/or percutaneous ethanol infection therapy, (123 ± 77 to 100 ± 60pmol/mL per h). Commensurate decreases of AFP and des-γ-carboxy prothrombin with GnT III activity were also observed after treatment. The Con A-non-reactive fraction (n= 21; 6.4 ± 2.3%) in patients with HCC after treatment was significantly lower than before (8.2 ± 2.4%). The present study suggests that GnT III activity is a possible and in the diagnosis and evaluation of HCC, especially when other tumour markers are negative. 相似文献
6.
F. ASANO H. MORIWAKI Y. SHIRATORI M. SHIMAZAKI T. SAKAI Y. KOSHINO N. MURAKAMI J. SUGIHARA H. OHNISHI K. SAITO Y. MUTO 《Journal of gastroenterology and hepatology》1993,8(3):228-231
Abstract The production rate of leukotriene B4 (LTB4) was measured using peripheral blood mononuclear cells (PBMC) in patients with fulminant hepatitis (FH) or other liver diseases. LTB4 in the culture media of PBMC under stimulation with Ca-ionophore was fractionated by HPLC and measured by radioimmunoassay. The production rate of LTB4 was elevated in 16 of 17 FH patients (3.3 ± 0.2 ng/106 cells for 5 min), while the production was below detectable level in patients with acute or chronic hepatitis and in healthy controls. In FH patients, the highest production rate of LTB4 was observed in the initial period of the disease. Enhanced LTB4 production may indicate the primed state of PBMC — the primed mononuclear cells are regarded as participating in the development of massive liver necrosis and of other organ failures in FH. 相似文献
7.
An autopsy case of Kasabach-Merritt syndrome in an infant has been reported. Clinically, multiple congenital subcutaneous hemangiomata, severe thrombocytopenia, considerable anemia and abnormal blood cells in the peripheral blood were observed. Postmortem examination revealed remarkable extramedullary hematopoiesis in various organs, hyperplasia of bone marrow and alveolar and glomerular dysplasia. Discussing these findings, we have reached an assumption that Kasabach-Merritt syndrome may be a state of developmental anomaly of angiomesenchyma. ACTA PATH. JAP. 20: 365–378, 1970. 相似文献
8.
MASARU SOGAMI SEIICHI ERA SHUNJI NAGAOKA KAZUO KUWATA KIMIHIRO KIDA KIYOSHI MIURA HIROSHI INOUYE EIJI SUZUKI SHIGEO HAYANO SHIGEKI SAWADA 《Chemical biology & drug design》1985,25(4):398-402
Human mercaptalbumin (HMA) and nonmercaptalbumin (HNA) could be separated by high-performance liquid chromatography (HPLC) at neutral pH. Using HPLC, the present authors found the nonmercapt-mercapt conversion (HNA ← HMA) during hemodialysis and the mercapt-nonmercapt conversion (HMA ← HNA) after hemodialysis in chronic renal failure, indicating HMA as the covalent carrier protein for sulfur-containing amino acids. 相似文献
9.
10.
KOUSUKE NAKANO OSAMU IKE HIROMI WADA SHIGEKI HITOMI YUKIHIKO AMANO IKUO OGITA NOBUKO NAKAI KANJI TAKADA 《The Journal of pharmacy and pharmacology》1997,49(5):485-490
A new oral sustained-release solid-dispersion preparation of cisplatin (cis-diamminedichloroplatinum(II); cisplatin) has been developed for administration to small experimental animals such as mice. This preparation was obtained by formulating cisplatin with the water-insoluble polymer ethylcellulose and with stearic acid in different ratios. In-vitro dissolution studies showed that cisplatin release characteristics were zero-order for the formulation cisplatin–ethylcellulose–stearic acid (1:10:5) and levels equilibrated 7 h after the start of the experiment. The availability of cisplatin from this preparation was evaluated both in rats and mice. The cisplatin preparation (20 mg kg?1) was administered orally to rats and the resulting curve of serum cisplatin levels against time was compared with that obtained after intravenous infusion (20 mg kg?1) to rats. By comparing the areas under serum concentration-time curves (AUCs), the bioavailability of cisplatin was estimated to be 31%. The mean residence time (MRT) of cisplatin solid dispersion was 6.13 ± 0.43 h, whereas the MRT of cisplatin administered by intravenous infusion was 3.89 ± 0.05 h. Serum cisplatin levels were maintained above 0.3 mg mL?1 (believed from our clinical studies to be the minimum effective concentration) for 24 h. The curve of serum cisplatin level against time suggested that cisplatin was released from the solid dispersion preparation in a sustained-release fashion. Similar levels were also maintained in mice for 24 h. The MRT of the cisplatin preparation was 10–16 h in mice, which is longer than that obtained after oral administration of the physical mixture. The serum free-cisplatin concentration was determined to be 0.10 mg mL?1 in mice serum in which the total cisplatin concentration was 0.30 mg mL?1. The free fraction of cisplatin in mice serum was the same as that in human patient serum. Pathological examination showed that this new sustained-release oral cisplatin preparation did not have any side effects on the gastrointestinal tract. These results suggest usefulness of this new solid-dispersion preparation for oral cisplatin therapy in lung cancer patients. 相似文献